CCN2 and Alzheimer disease: Our analysis thus suggests that pathological expression of CTGF and SPARC, by opposing the effects of increased proangiogenic factor (FGF2, HIF1A, ANGPT2) expression, impair angiogenesis progressively in AD as pathological tissue Aβ and pTau increase.